Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emricasan in NASH Fibrosis
NCT02686762Phase 2Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Jan 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of emricasan in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Conatus Pharmaceuticals Inc. Primary endpoint: Fibrosis improvement by at least one stage without worsening of steatohepatitis at Week 72. Started Jan 2016; status: completed.
02
Drugs
emricasan
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02686762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686762.